Open AccessEfficacy and tolerability of calcium channel alpha-2-delta ligands in psychiatric disorders
Author(s) -
O. Vasiliu,
D. Vasile,
Andrei G. Mangalagiu,
Bogdan M. Petrescu,
Corina Tudor,
D. Ungureanu,
Cristian A. Cândea
Publication year - 2017
Publication title -
romanian journal of military medicine
Language(s) - English
Resource type - Journals
eISSN - 2501-2312
pISSN - 1222-5126
DOI - 10.55453/rjmm.2017.120.2.4
Subject(s) - tolerability , anxiolytic , medicine , anxiety , psychiatry , calcium channel , pregabalin , pharmacology , antidepressant , clinical trial , gabapentin , calcium , adverse effect , alternative medicine , pathology
Matching drugs with anxiolytic properties- but without the potential of inducing dependence or abuse- with clinical manifestations of various affective disorders is a very important challenge for psychiatrists. Although the first line of pharmacologic treatment for anxiety disorders remains antidepressants with serotoninergic properties, calcium channel alpha-2-delta ligands are adjuvant agents which could be useful for augmenting antidepressant agents’ clinical effects. Unfortunately, calcium channel alpha-2-delta ligands efficacy and tolerability are not very well known, due to a lack of large scale, randomized, placebo-controlled trials focused on psychiatric disorders. Data regarding pregabalin and gabapentin pharmacology and clinical effects are reviewed and conclusions with pragmatically impact based on the discovered evidence are formulated accordingly.